Valuation : Enovis Corporation

Market Cap 1.46B 7.53B 1.25B 1.17B 1.07B 2.02B 139B 2.02B 13.86B 5.42B 70.09B 5.47B 5.35B 232B P/E 2026 *
87.1x
P/E 2027 * 23.5x
Enterprise Value 2.67B 13.82B 2.29B 2.15B 1.97B 3.7B 255B 3.71B 25.42B 9.94B 129B 10.03B 9.81B 425B EV / Sales 2026 *
1.14x
EV / Sales 2027 * 1.04x
Free-Float
98.38%
Yield 2026 *
-
Yield 2027 * -
1 day+0.03%
Current month+2.18%
1 month+2.18%
3 months-0.30%
6 months-15.37%
Current year-15.37%
1 month 32.76
Extreme 32.76
34.59
Current year 26.85
Extreme 26.85
34.59
1 year 26.85
Extreme 26.85
43.24
3 years 26.85
Extreme 26.85
80.96
5 years 26.85
Extreme 26.85
81.75
10 years 26.85
Extreme 26.85
81.75
Manager TitleAgeSince
Chief Executive Officer 61 12/05/2025
Director of Finance/CFO 47 01/01/2023
Chief Tech/Sci/R&D Officer - 01/01/2026
Director TitleAgeSince
Director/Board Member 55 13/05/2008
Director/Board Member 67 21/09/2010
Chairman 64 21/05/2025
Change 5-day change 1-year change 3-year change Capi.($)
+0.03%0.00% - - 1.46B
-1.01%-0.41%-16.99%+17.26% 126B
+0.14%+0.37%-22.28%-0.05% 12.24B
+0.34%-2.07%+90.34%+144.60% 10.65B
+2.13%-4.21%-51.63%-68.92% 4.21B
+0.57%+4.02%-22.01%+58.76% 2.77B
-0.77%+0.24%-33.46%-71.91% 1.79B
+1.12%-0.84%-23.32%-12.99% 1.66B
+0.47%-3.59%-36.96%-38.68% 1.59B
Average +0.35%-0.58%-14.54%+3.51% 20.17B
Weighted average by Cap. -0.69%-2.62%-11.74%+20.97%

Financials

2026 *2027 *
Net sales 2.34B 12.1B 2.01B 1.88B 1.72B 3.24B 223B 3.25B 22.26B 8.7B 113B 8.78B 8.59B 373B 2.45B 12.69B 2.11B 1.97B 1.81B 3.4B 234B 3.41B 23.35B 9.13B 118B 9.21B 9.01B 391B
Net income 11.5M 59.49M 9.87M 9.24M 8.46M 15.94M 1.1B 15.99M 109M 42.78M 554M 43.18M 42.24M 1.83B 60.85M 315M 52.23M 48.9M 44.78M 84.35M 5.81B 84.59M 579M 226M 2.93B 228M 224M 9.69B
Net Debt 1.21B 6.28B 1.04B 976M 894M 1.68B 116B 1.69B 11.56B 4.52B 58.47B 4.56B 4.46B 194B 1.08B 5.61B 931M 872M 798M 1.5B 104B 1.51B 10.32B 4.04B 52.22B 4.07B 3.98B 173B
Logo Enovis Corporation
Enovis Corporation is a medical technology company. It is focused on developing clinically differentiated solutions by manufacturing and distributing high-quality medical devices with a range of products used for reconstructive surgery, rehabilitation, pain management and physical therapy. It operates through two segments: Prevention & Recovery and Reconstructive. The Prevention & Recovery segment provides orthopedic and recovery science solutions, including devices, software, and services across the patient care continuum from injury prevention to rehabilitation after surgery, injury, or from degenerative diseases. The Prevention & Recovery products are marketed under several brand names, such as DJO. The Reconstructive segment provides surgical implant solutions, offering a comprehensive suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger and surgical productivity tools. It also operates a Enovis Growth eXcellence business system (EGX).
Employees
7,802
Date Price Change Volume
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
25.25USD
Average target price
40.83USD
Spread / Average Target
+61.72%

Quarterly revenue - Rate of surprise